Of note, α7 nAChRs agonists, such as encenicline has been studied in clinical trials in both Alzheimer’s disease and schizophrenia and while animal models showed consistent efficacy all human clinical trials failed identifying a translational gap (NCT01969136 and NCT01969123) (Prickaerts et al., 2012). The gene discussed is CHRNA7; the disease is early-onset autosomal dominant Alzheimer disease.